In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies

Abstract excerpt

In silico immunogenicity risk assessment has been an important step in the development path for many biologic therapeutics, including monoclonal antibodies. Even if the source of a given biologic is 'fully human', T cell epitopes that are contained in the sequences of the biologic may activate the immune system, enabling the development of anti-drug antibodies that can reduce drug efficacy and may contribute to...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Biosimilars and Bioanalytical Methods
• Share to Monoclonal and Polyclonal Antibodies Research
• Share to vaccines and immunoinformatics approaches